A. Vanderstraeten

发表

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy

F. Amant, G. Verbist, S. Tuyaerts, 2014, Cancer Immunology, Immunotherapy.

The immune system in the normal endometrium and implications for endometrial cancer development.

F. Amant, S. Tuyaerts, A. Vanderstraeten, 2015, Journal of reproductive immunology.

Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations

Brit B. Turnbull, H. Kohrt, B. Narasimhan, 2014, Journal of Translational Medicine.

In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer

F. Amant, G. Verbist, S. Tuyaerts, 2016, International journal of molecular sciences.

Dendritic cell immunotherapy in uterine cancer

F. Amant, A. Coosemans, S. V. Van Gool, 2014, Human vaccines & immunotherapeutics.

Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.

F. Amant, Z. Berneman, A. Coosemans, 2013, Anticancer research.

In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer

F. Amant, G. Verbist, S. Tuyaerts, 2015, Journal of immunotherapy.

Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.

F. Amant, Z. Berneman, A. Coosemans, 2013, Anticancer research.

External validation of non-imaging models for predicting distant metastasis in patients with endometrial cancer.

F. Amant, I. Vergote, M. Koskas, 2016, Gynecologic oncology.

Evaluation of models to predict lymph node metastasis in endometrial cancer: A multicentre study.

D. Timmerman, I. Vergote, F. Amant, 2016, European journal of cancer.